Wockhardt launches insomnia drug Zolpidem in US

New Delhi, May 21 (UNI) Wockhardt Ltd today said it has received USFDA approval for marketing Zolpidem tablets in the US market.

Zolpidem, which has 2.2 billion dollars market in the US, is widely used to treat insomnia (sleep disorder).

''The key to our success in the competitive US market is our ability to continuously add to the breadth and depth of our product portfolio,'' company's Chairman Habil Khorakiwala said.

The company will also be launching Lisinopril tablets in the US market very soon, he added.

The new drug is the 20th product to be launched in the US market by Wockhardt and had received six USFDA approvals in the last two months.

The company manufactures Zolpidem tartrate API at its USFDA approved facility at Ankleshwar, Gujarat, while the tablets are manufactured at formulation plant at Waluj, Maharashtra.

UNI